---
title: "nivofgfr2"
date: "2024-07-14"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[mgc1l]]

# nivofgfr2

- **Design:** Phase 2, single-arm, multi-center trial
- **Number of patients:** 23 patients enrolled
- **Patients characteristics:** HER2-negative with centrally confirmed expression of PD-L1 and FGFR2
- **Agent:** Nivolumab 360 mg with CapeOX (capecitabine and oxaliplatin)
- **Treatment line:** First-line
- **Trial Acronym/NCTId Number:** NIVOFGFR2, NCT05859477

| Parameter       | Result     |
| --------------- | ---------- |
| 1-year PFS rate | 30.4%      |
| Median PFS      | 6.2 months |
| ORR             | 21.7%      |

- **Highlight of toxicity:** Grade â‰¥3 treatment-related adverse events reported in 9 (39.1%) patients
- **One-line summarize:** Nivolumab in combination with chemotherapy shows modest efficacy and acceptable safety profile in patients with FGFR2-positive, PD-L1-positive metastatic GC.

### References

> [Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2. | Journal of Clinical Oncology](https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.303)
